Discover the science behind Tesamorelin, a research peptide targeting visceral fat and promoting health span. Kris Gethin breaks down its mechanisms, research findings, and implications for fat distribution and longevity.
Tesamorelin is a synthetic analog of growth hormone release hormone (GHRH), stimulating the pituitary to release endogenous growth hormone rather than supplying synthetic GH.
It primarily targets deep visceral fat, especially around organs, instead of just superficial subcutaneous fat.
Visceral fat is linked to metabolic diseases, inflammation, insulin resistance, and overall aging; reducing it can extend health span.
Research shows Tesamorelin reduces visceral fat by approximately 14-18% over 26 weeks without significant weight change.
Unlike appetite suppressants like GLP-1 agents, Tesamorelin is considered weight-neutral, aiming for fat redistribution rather than broad weight loss.
The effects on body composition include improved fat distribution, preservation of lean mass, and healthier metabolic markers.
It can influence glucose tolerance and may cause fluid retention, joint pain, or injection site reactions, especially in older or metabolic-compromised individuals.
Optimizing lifestyle factors such as sleep, nutrition, and stress management is crucial, as environment impacts visceral fat accumulation.
Measuring waist circumference, visceral fat via imaging, blood markers, and metabolic health indicators are essential for tracking progress.
Use of peptides like Tesamorelin should be under medical supervision within a broader health and lifestyle strategy.
Timestamps:
00:00 - Introduction to Kris Gethin and peptide content channels
00:27 - What is Tesamorelin and its clinical relevance
00:56 - Mechanism: GHRH analog stimulating growth hormone release
01:23 - Differentiating Tesamorelin from other peptides and its origin
01:50 - Impact on visceral and liver fat, and fat loss models
02:20 - Growth hormone axis and visceral fat interaction
02:44 - Education disclaimer and medical considerations
03:14 - Historical context: HIV-related lipodystrophy and fat redistribution
04:12 - Visceral vs subcutaneous fat differences
04:42 - Psychological and health impacts of visceral fat
05:10 - How Tesamorelin targets internal fat and body composition
05:37 - Fat loss measurement—imaging and metabolic markers
06:06 - Clinical trial outcomes: visceral fat reduction statistics
06:33 - Fat redistribution versus scale weight changes
07:00 - Growth hormone effects on adipose tissue and fat mobilization
07:29 - Localized fat loss and research evidence
07:58 - Impact on organs around visceral fat
08:24 - Clinical trial insights on visceral fat change over 26 weeks
08:53 - Quantitative results: visceral fat reduction percentages
09:21 - Fat loss success indicators: visceral fat, waist size, metabolics
09:49 - Why weight-neutral interventions are vital for health span
10:18 - Visceral fat's role in metabolic aging and liver health
10:45 - External factors influencing visceral fat and lifestyle importance
11:15 - Liver fat, insulin resistance, and metabolic health
11:45 - Impact on HIV-associated liver issues and relevance to non-HIV populations
12:14 - Liver fat's role in glucose regulation and overall health
12:42 - The importance of measuring internal fat and metabolic health
13:10 - How lifestyle interacts with peptide effects and fat storage
13:38 - The complex role of growth hormone and IGF-1 in body health
14:06 - Risks, side effects, and precautions with Tesamorelin
14:36 - The importance of medical oversight and blood work monitoring
15:06 - Peptides as part of broader lifestyle strategies
15:35 - Influence of environment and lifestyle on visceral fat
16:04 - The significance of fat distribution for health and appearance
16:33 - Misconceptions: fat loss vs fat redistribution and muscle preservation
17:02 - The balance of growth hormone signaling and metabolic risks
17:31 - Regulating GH pathways for optimal health outcomes
18:00 - Side effects: fluid retention, joint pain, sleep issues
18:29 - Medical considerations: conditions requiring caution
18:58 - The impact of growth hormone on glucose metabolism
19:27 - Reversibility: why maintaining lifestyle is key to permanence
19:54 - The importance of measuring progress with tools beyond the scale
20:22 - Integrating blood tests, imaging, and lifestyle logs
20:49 - Systemic approach: nutrition, training, stress, sleep
21:18 - Visceral fat as a reflection of metabolic health
21:46 - Peptides as lifestyle adjuncts, not standalone solutions
22:16 - Why deep visceral fat should be prioritized for health risk reduction
22:46 - Visuals of fat distribution and fat loss versus muscle depletion
23:15 - Peptides' role in health span, not just aesthetics
23:44 - Comparing Tesamorelin with traditional growth hormone therapies
24:12 - Muscle gain limitations and realistic expectations
24:39 - Peptides as tools for fat and metabolic health, not muscle building
25:09 - Broader issues: environment, lifestyle, and societal factors in obesity
25:38 - The importance of healthy habits for lasting results
26:05 - Changing environment to sustain fat loss gains
26:33 - Focus on targeted fat loss and biological change over scale weight
27:01 - Practical advice: measure waist, blood markers, and lifestyle factors
27:31 - Summary: deep visceral fat as a sign of aging; the role of Tesamorelin
27:59 - Trusted peptide suppliers and quality control
28:28 - Final thoughts and encouragement for responsible research and use
Resources & Links:
Biohacked AF Community & Education
Nova Prime Labs (preferred peps)
Connect with Kris Gethin:
Twitter
Instagram
Website
USA